CROs march towards Eastern Europe

By Kirsty Barnes

- Last updated on GMT

Related tags: Clinical trials, Clinical trial, Eastern europe

As contract research organisations (CROs) continue to search for
cost-effective countries in which to operate, the clinical trials
market is increasingly expanding into emerging economies. Central
and Eastern Europe are continuing to experience strong activity in
this area.

Over the last decade the number of multi-centre clinical trials in the Central and Eastern Europe region has been growing on average at an annual rate of 30 per cent and this growth is expected to continue.

Analysts Frost & Sullivan predict year-on-year growth for the European CRO market of 10.4 per cent up to 2007, when it will be worth an estimated $4.3 bn (€3.5 bn), primarily driven by the increasing attractiveness of Eastern Europe to drug developers in both the US and Western Europe.

Last week, leading CRO >Covance​ further expanded its presence in the region, opening a new clinical development office in Prague, Czech Republic.

The company, which already has existing clinical development offices in Warsaw, Poland and Budapest, Hungary, will use the new Prague office to support further clinical trial operations in the Czech Republic and Slovakia.

"We predicted and have seen the growth of Central and Eastern Europe as a region in which to perform clinical trials, because of its clinical trial infrastructure, suitable patient populations and medical expertise in a number and variety of indications"​, said Dr. Alan Wood, general manager, Europe and Asia-Pacific for Covance Clinical and Periapproval Services.

Meanwhile UK firm >Synexus Clinical Research​ has just bought Polish clinical trials company Skandynawskie Centrum Medyczne (SCM) - its first acquisition since joining AIM in November 2005.

The company plans to use this acquisition "as a stepping stone to exploit growing opportunities in Central and Eastern Europe and further expand both through organic growth and further acquisitions,"​ said Michael Fort, chief executive of Synexus.

The SCM deal also brings contracts with a number of customers in the pharmaceutical industry, who are not currently customers of Synexus, in addition to licences to open further centres in Poland and in neighbouring Ukraine.

The acquisition follows the company's strategy of expansion through selective acquisitions, concentrating on Synexus' core activity of patient recruitment for later stage clinical trials, with particular focus on the exploitation of growing opportunities for clinical trials and patient recruitment in emerging economies.

Last month Synexus entered India's burgeoning clinical research market, setting up the country's first patient-recruitment site management organisation (SMO) with IRL, a subsidiary of the Indian Clinical Research Institute.

Related news

Show more

Related products

show more

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 20-Jun-2022 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Governing and Maintaining Clinical Data Standards

Governing and Maintaining Clinical Data Standards

Veeva | 10-May-2022 | Technical / White Paper

Investing in data standards plays a huge role in improving the quality of clinical studies. But often, people don’t use the standards correctly, there...

Related suppliers

Follow us

Products

View more

Webinars